Home › Left Ventricular Hypertrophy › NCT03549559
Imaging Histone Deacetylase in the Heart
RecruitingHealthy volunteers welcome
Imaging of Histone Deacetylase in the Heart
Who can join
Ages 18 to 85 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: Group 1: Healthy Volunteers (n = 30) * Healthy adults with no known history of medical disease * Age 18-85 years * No history cardiovascular disease * Ability to provide informed consent Group 2: Patients with Diabetes (n = 16) * Age 18-85 years * Diagnosis of diabetes * Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction * Ability to provide informed consent Group 3: Patients with Aortic Stenosis (n = 50) * Age 18-85 years * Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis * Ability to provide informed consent Exclusion Criteria: * Known contraindication to MRI
About the study
The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.
What is being tested
- 11C-Martinostat (drug)
- PET-MRI (device)
Sponsor: Massachusetts General Hospital · Participants: 96 · Started: Sep 7, 2018
Contact the study team
- David E Sosnovik, MD · Phone: 617-724-3407
- Anne L Philip, MPH · Phone: 617-726-0431
Official record on ClinicalTrials.gov — NCT03549559
Locations in the U.S.
| Massachusetts | Massachusetts General Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.